TEE
LJPC

Tibra Equities Europe’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Tibra Equities Europe’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-72,600
Closed -$311K – 272
2021
Q2 		$311K Buy
+72,600
New +$311K 0.1% 167

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
KT
Kevin Tang $783 AUM 75.59% 1-Year Est. Return

Tibra Equities Europe's LJPC Position: Q3 2021 in Review

Tibra Equities Europe sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2021, closing a stake of 72,600 shares — an estimated $311K sold.

Tibra Equities Europe first reported a position in LJPC in Q2 2021 and held it in 1 quarter. The position peaked at $311K in Q2 2021. 54 funds tracked by Wall St. Rank hold LJPC as of Q3 2021.

  • Tibra Equities Europe reported no remaining La Jolla Pharmaceutical Company position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 72,600 La Jolla Pharmaceutical Company shares in Q3 2021, an estimated $311K.
  • Tibra Equities Europe first reported a position in La Jolla Pharmaceutical Company in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's La Jolla Pharmaceutical Company position peaked at $311K in Q2 2021.
  • 54 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.